Biopharma stocks to see increased M&A activity amid Eli...

2026-01-08 13:15:11 ET More on biotech, biopharma Biotech: Time For A Pause To Start 2026 2026 Market Outlook: S&P 500 Looks Expensive, But Biotech Could Outperform Under The Hood iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector Short bets on S&P 500 Healthcare sector rises to 2.12% in November; MRNA stays most shorted stock SA Quant ranks Goldman's top 20 ETFs with the largest hedge fund ownership Read the full article on Seeking Alpha For further details see: Biopharma stocks to see increased M&A activity amid Eli Lilly-Ventyx deal